醫藥組成物用於製備抑制小腦萎縮症藥物之用途 METHOD FOR TREATING SPINOCEREBELLAR ATAXIAS

專利類型

發明

專利國別 (專利申請國家)

美國

專利申請案號

14/996,271

專利證號

US 10,213,470 B2

專利獲證名稱

醫藥組成物用於製備抑制小腦萎縮症藥物之用途 METHOD FOR TREATING SPINOCEREBELLAR ATAXIAS

專利所屬機關 (申請機關)

國立臺灣師範大學

獲證日期

2019/02/26

技術說明

本研究利用HPLC分析中藥製劑芍藥甘草湯活性成份Paeoniflorin及Ammonium glycyrrhizinate，並以DPPH自由基清除測試顯示芍藥甘草湯具自由基清除能力。利用LPS 刺激的RAW 264.7及BV-2細胞，發現芍藥甘草湯具抗發炎性。細胞前處理芍藥甘草湯後再誘導表現第三型小腦萎縮症ATXN3/Q75-GFP蛋白，能抑制細胞中不正常摺疊的ATXN3/Q75蛋白聚集，並改善第十七型小腦萎縮症小鼠在滾輪測試的運動協調及腳印分析的步態行為。結合先前描述的有關Paeoniflorin活化伴隨蛋白表現及Ammonium glycyrrhizinate增強粒線體新生及抗氧化功能的結果，顯示芍藥甘草湯作用在增強伴隨蛋白表現、粒線體新生、抗氧化及抗發炎活性，來抑制第三型小腦萎縮症細胞的多麩醯胺聚集，並改善第十七型小腦萎縮症疾病鼠的運動失調症狀，故在臨床上有潛能被應用來治療小腦萎縮症。 In this study, we used HPLC to examine the active compounds paeoniflorin and ammonium glycyrrhizinate in Chinese medicine formula Shao Yao Kan Tsao Tang (SK Tang). DPPH scavenging assay revealed that SK Tang displayed free radical scavenging activity. Using LPS-stimulated RAW 264.7 and BV-2 cells, SK Tang also displayed good anti-inflammatory activity. Meanwhile, misfolded polyQ aggregates can be significantly prohibited by SK Tang pre-treatment in 293 cells with ATXN3/Q75-GFP expression. Furthermore, both motor coordination and gait behavior were significantly improved in the SK Tang-treated SCA17 mice. Together with the previously described enhancing chaperone expression by paeoniflorin and increasing mitochondrial biogenesis and antioxiation by ammonium glycyrrhizinate, our results demonstrated SK Tang prohibit polyQ-aggregation in SCA3 cells and improve ataxia phenotype in SCA17 mice.

備註

連絡單位 (專責單位/部門名稱)

產學合作組

連絡電話

77341329

網址